Three agents have recently been approved to reduce the risk of stroke and embolism, and one agent is in phase 3 trials. These drugs cause less serious bleeding and are simpler to manage, compared with warfarin, but they are not without their risks.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638402 | PMC |
Publication Analysis
Top Keywords
improving anticoagulation
4
anticoagulation management
4
management patients
4
patients atrial
4
atrial fibrillation
4
fibrillation three
4
three agents
4
agents approved
4
approved reduce
4
reduce risk
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!